Corroborating this line of evidence, patients with previous decreased ACE2 activity, such as in the elderly, systemic arterial hypertension (SAH), diabetes mellitus (DM), and cardiovascular diseases (CVDs), are more subject to longer hospitalizations and death from COVID-19, that is, tend to worsen the disease, and such conditions are considered risk factors [1, 3, 17–19]. Here, ACE2 is linked to COVID-19.